Cytokinetics (CYTK) Capital Expenditures (2010 - 2026)

Cytokinetics (CYTK) has reported Capital Expenditures for 17 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 4.7% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $25.1 million (up 178.31% YoY), while the FY2025 annual figure was $24.8 million, up 641.61% from the prior year.
• Capital Expenditures declined to $5.9 million in Q1 2026 per CYTK's latest filing, from $22.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $22.7 million in Q4 2025 and bottomed at -$2.8 million in Q2 2025.
• Historically, Capital Expenditures has averaged $2.8 million across 5 years, with a median of $899500.0 in 2022.
• On a YoY basis, Capital Expenditures climbed as much as 688.03% in 2025 and fell as far as 4267.65% in 2025.
• Cytokinetics' Capital Expenditures stood at $3.2 million in 2022, then tumbled by 141.78% to -$1.3 million in 2023, then surged by 315.31% to $2.9 million in 2024, then jumped by 688.03% to $22.7 million in 2025, then slumped by 73.9% to $5.9 million in 2026.
• Business Quant data shows CYTK's Capital Expenditures at $5.9 million in Q1 2026, $22.7 million in Q4 2025, and -$742000.0 in Q3 2025.